M. Spears

发表

In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer

J. Bartlett, D. Cameron, E. Mallon, 2012, Breast Cancer Research and Treatment.

The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer

J. Bartlett, M. Spears, 2009, Expert opinion on therapeutic targets.

Proximity ligation assays for isoform‐specific Akt activation in breast cancer identify activated Akt1 as a driver of progression

G. Kerr, J. Bartlett, D. Cameron, 2012, The Journal of pathology.

Thepotentialroleofestrogen receptorsandtheSRCfamily astargetsforthetreatmentof breastcancer

J. Bartlett, M. Spears, 2009 .

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

A. Gown, S. Leung, T. Nielsen, 2022, Modern Pathology.

Authors' Reply

G. Kerr, J. Bartlett, D. Cameron, 2013, The Journal of pathology.

ISOWN: accurate somatic mutation identification in the absence of normal tissue controls

Lincoln D. Stein, J. McPherson, J. Bartlett, 2017, Genome Medicine.

Benchmarking to the Gold Standard: Hyaluronan‐Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture

Gary D Bader, D. Cescon, J. Bartlett, 2019, Advanced materials.

Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers.

Lincoln D. Stein, J. McPherson, P. Boutros, 2019, JCO precision oncology.

Expression of activated type I receptor tyrosine kinases in early breast cancer

G. Kerr, J. Bartlett, D. Cameron, 2012, Breast Cancer Research and Treatment.

Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study

Anagha P. Jadhav, A. Gown, M. Ellis, 2022, Modern Pathology.

In situ quantification of HER2–protein tyrosine kinase 6 (PTK6) protein–protein complexes in paraffin sections from breast cancer tissues

A. Feuchtinger, H. Höfler, J. Bartlett, 2010, British Journal of Cancer.

Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer.

J. Bartlett, A. Munro, M. Spears, 2008, Biomarkers in medicine.

A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial

Bingshu E. Chen, P. Boutros, J. Bartlett, 2016, Oncotarget.

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance

J. Reis-Filho, J. Bartlett, A. Mackay, 2014, BMC Cancer.

Human Epidermal Growth Factor Receptor Dimerization Analysis in Breast Cancer Diagnosis

J. Bartlett, M. Spears, 2009, Molecular Diagnosis & Therapy.

The p160 ER co-regulators predict outcome in ER negative breast cancer

S. Hilsenbeck, G. Kerr, J. Bartlett, 2011, Breast Cancer Research and Treatment.

In situ quantification of HER 2-protein tyrosine kinase 6 ( PTK 6 ) protein-protein complexes in paraffin sections from breast cancer tissues

A. Feuchtinger, H. Höfler, H. Braselmann, 2010 .

Validated or not validated? That is the question.

J. Bartlett, K. Pritchard, M. Spears, 2014, Journal of the National Cancer Institute.

Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer

P. Boutros, J. Bartlett, C. Yao, 2018, Journal of Ovarian Research.

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer

Lincoln D. Stein, P. Boutros, J. Bartlett, 2016, Breast Cancer Research.

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials

P. Boutros, J. Bartlett, Fouad Yousif, 2015, Oncotarget.

protein-protein complexes in paraffin sections from breast cancer tissues

A. Feuchtinger, H. Braselmann, M. Aubele, 2010 .

A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial

Bingshu E. Chen, P. Boutros, L. Shepherd, 2016, Oncotarget.